Drug intelligence / Profile preview

SIG-1191

Development stage: Preclinical
Lead developer: Signum Biosciences
Modality: Small Molecules
Administration: Topical

Overview

SIG-1191 is a small molecule isoprenylcysteine (IPC) analog developed by Signum Biosciences. Chemically identified as N-acetylglutaminoyl-S-farnesyl-L-cysteine, it is designed to modulate the activity and expression of Aquaporin-3 (AQP3), a membrane protein that facilitates the transport of water and glycerol across skin cells. By targeting AQP3, SIG-1191 aims to enhance skin hydration and improve the skin's barrier function. It is primarily being developed for topical dermatological and cosmetic applications, specifically targeting skin dryness and the appearance of under-eye dark circles.

Other names: N-Acetylglutaminoyl-S-Farnesyl-L-cysteineSIG-1191™

Targets

AQP3 (Aquaporin-3 channel protein)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))MEK

Beyond the preview

Go deeper on SIG-1191.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIG-1191.

Explore the full profile